Ardelyx, Inc. (NASDAQ:ARDX) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET

Company Participants

Caitlin Lowie - Vice President of Corporate Communications & Investor Relations
Michael Raab - President & Chief Executive Officer
Susan Rodriguez - Chief Commercial Officer
Justin Renz - Chief Financial Officer & Chief Operations Officer

Conference Call Participants

Louise Chen - Cantor Fitzgerald
Yigal Nochomovitz - Citi
Dennis Ding - Jefferies
Laura Chico - Wedbush
Roanna Ruiz - Leerink Partners
Ryan Deschner - Raymond James
Joseph Thome - TD Cowen
Ed Arce - H.C. Wainwright.
Matt Kaplan - Ladenburg Thalmann

Operator

Good afternoon and welcome to the Ardelyx Second Quarter 2024 Conference Call. All participants will be in listen-only mode. [Operator Instructions]. After today's presentation, there will be an opportunity to ask questions. [Operator instructions]. Please note, this event is being recorded.

I would now like to turn the conference over to Caitlin Lowie, Vice President of Corporate Communications and Investor Relations at Ardelyx. Please go ahead.

Caitlin Lowie

Thank you. Good afternoon and welcome to our second quarter 2024 financial results call. During this call, we will refer to the press release issued earlier today which is available on the Investors section of the company's website at ardelyx.com.

During this call, we will be making forward-looking statements that are subject to risks and uncertainties. Our actual results may differ materially from those described. We encourage you to review the risk factors in our most recent quarterly report on Form 10-Q that was filed today and can be found on our website @ardelyx.com. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so even if our views change.

Our President and CEO, Mike Raab, and Chief Financial and Operations Officer, Justin Renz, will share prepared remarks before we open the call to questions.

I will now hand the call over to Mike.

Michael Raab

Thank you, Caitlin, and good afternoon, everyone. It is great to be back together to discuss another quarter's strong performance.

Across all fronts, we continue to drive exceptional progress. IBSRELA's growth momentum continued at a strong pace with another quarter of meaningful gains with revenue growing 25% compared to the first quarter of 2024 and nearly doubled compared to the second quarter of last year. This performance demonstrates the important role IBSRELA is playing addressing the large unmet need among patients with IBS-C.